Can a cancer drug boost stem cell transplants for rare T-Cell cancers?
NCT ID NCT02512497
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 40 times
Summary
This early-phase study tested adding the drug romidepsin to standard chemotherapy before and after a stem cell transplant in 23 people with certain T-cell cancers. The goal was to find a safe dose and see if the combination could help control the cancer. Participants received the drugs before transplant and then romidepsin afterward to try to prevent relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Ohio State University Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.